Broad coverage of neutralization-resistant SIV strains by second-generation SIV-specific antibodies targeting the region involved in binding CD4

Both SIV and SHIV are powerful tools for evaluating antibody-mediated prevention and treatment of HIV-1. However, owing to a lack of rhesus-derived SIV broadly neutralizing antibodies (bnAbs), testing of bnAbs for HIV-1 prevention or treatment has thus far been performed exclusively in the SHIV NHP model using bnAbs from HIV-1-infected individuals. Here we describe the isolation and characterization of multiple rhesus-derived SIV bnAbs capable of neutralizing most isolates of SIV. Eight antibodies belonging to two clonal families, ITS102 and ITS103, which target unique epitopes in the CD4 binding site (CD4bs) region, were found to be broadly neutralizing and together neutralized all SIV strains tested. A rare feature of these bnAbs and two additional antibody families, ITS92 and ITS101, which mediate strain-specific neutralizing activity against SIV from sooty mangabeys (SIVsm), was their ability to achieve near complete (i.e. 100%) neutralization of moderately and highly neutralization-resistant SIV. Overall, these newly identified SIV bnAbs highlight the potential for evaluating HIV-1 prophylactic and therapeutic interventions using fully simian, rhesus-derived bnAbs in the SIV NHP model, thereby circumventing issues related to rapid antibody clearance of human-derived antibodies, Fc mismatch and limited genetic diversity of SHIV compared to SIV.

[1]  M. Roederer,et al.  Evaluation of chimeric antigen receptor T cell therapy in non-human primates infected with SHIV or SIV , 2021, PloS one.

[2]  N. Garrett,et al.  Clinical Trials of Broadly Neutralizing Monoclonal Antibodies for Human Immunodeficiency Virus Prevention: A Review , 2020, The Journal of infectious diseases.

[3]  B. Haynes,et al.  Multiple roles for HIV broadly neutralizing antibodies , 2019, Science Translational Medicine.

[4]  Chaim A. Schramm,et al.  Isolation and Structure of an Antibody that Fully Neutralizes Isolate SIVmac239 Reveals Functional Similarity of SIV and HIV Glycan Shields. , 2019, Immunity.

[5]  J. Mullikin,et al.  Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization , 2019, Cell.

[6]  Yifan Li,et al.  The breadth of HIV-1 neutralizing antibodies depends on the conservation of key sites in their epitopes , 2019, PLoS Comput. Biol..

[7]  J. Bloom,et al.  An Antigenic Atlas of HIV‐1 Escape from Broadly Neutralizing Antibodies Distinguishes Functional and Structural Epitopes , 2019, Immunity.

[8]  J. Mascola,et al.  Structural Survey of Broadly Neutralizing Antibodies Targeting the HIV-1 Env Trimer Delineates Epitope Categories and Characteristics of Recognition. , 2019, Structure.

[9]  J. Mascola,et al.  Vectored delivery of anti-SIV envelope targeting mAb via AAV8 protects rhesus macaques from repeated limiting dose intrarectal swarm SIVsmE660 challenge , 2018, PLoS pathogens.

[10]  D. Burton,et al.  Recent progress in broadly neutralizing antibodies to HIV , 2018, Nature Immunology.

[11]  L. McCoy.  The expanding array of HIV broadly neutralizing antibodies , 2018, Retrovirology.

[12]  P. Moore,et al.  Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers , 2018, Retrovirology.

[13]  J. Mascola,et al.  HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure. , 2018, Immunity.

[14]  T. Kepler,et al.  Structure and Diversity of the Rhesus Macaque Immunoglobulin Loci through Multiple De Novo Genome Assemblies , 2017, Front. Immunol..

[15]  B. Korber,et al.  Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail , 2017, Science Translational Medicine.

[16]  B. Korber,et al.  Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge , 2017, Science Translational Medicine.

[17]  Ruchi M. Newman,et al.  Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys , 2017, Journal of Virology.

[18]  W. Johnson,et al.  Analysis of SIVmac Envelope-Specific Antibodies Selected Through Phage Display. , 2017, AIDS research and human retroviruses.

[19]  G. B. Karlsson Hedestam,et al.  Production of individualized V gene databases reveals high levels of immunoglobulin genetic diversity , 2016, Nature Communications.

[20]  Tongqing Zhou,et al.  Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth. , 2016, Immunity.

[21]  H. Liao,et al.  Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies , 2016, Journal of Virology.

[22]  M. Nussenzweig,et al.  Sequencing and cloning of antigen-specific antibodies from mouse memory B cells , 2016, Nature Protocols.

[23]  J. Mascola,et al.  Multiple Antibody Lineages in One Donor Target the Glycan-V3 Supersite of the HIV-1 Envelope Glycoprotein and Display a Preference for Quaternary Binding , 2016, Journal of Virology.

[24]  Peter D. Kwong,et al.  SONAR: A High-Throughput Pipeline for Inferring Antibody Ontogenies from Longitudinal Sequencing of B Cell Transcripts , 2016, Front. Immunol..

[25]  F. Alt,et al.  Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires , 2016, Cell.

[26]  J. Mascola,et al.  A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges , 2016, Nature.

[27]  J. Mascola,et al.  Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability , 2016, PLoS pathogens.

[28]  J. Hoxie,et al.  Derivation and Characterization of a CD4-Independent, Non-CD4-Tropic Simian Immunodeficiency Virus , 2016, Journal of Virology.

[29]  C. Apetrei,et al.  Animal Models for HIV Cure Research , 2016, Front. Immunol..

[30]  J. Mascola,et al.  Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody , 2015, Journal of Virology.

[31]  D. Burton,et al.  Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies , 2015, PLoS pathogens.

[32]  Cinque S. Soto,et al.  Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors , 2015, Cell.

[33]  B. Pulendran,et al.  Characterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope , 2015, Journal of Virology.

[34]  D. Montefiori,et al.  Pharmacokinetics and Immunogenicity of Broadly Neutralizing HIV Monoclonal Antibodies in Macaques , 2015, PloS one.

[35]  Patrice Duroux,et al.  IMGT®, the international ImMunoGeneTics information system® 25 years on , 2014, Nucleic Acids Res..

[36]  Scott D Boyd,et al.  Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies. , 2014, Cell host & microbe.

[37]  Young Do Kwon,et al.  Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection against Lentiviral Infection In Vivo , 2014, Journal of Virology.

[38]  B. Korber,et al.  Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection , 2014, AIDS.

[39]  J. Mascola,et al.  Isolation of human monoclonal antibodies from peripheral blood B cells , 2013, Nature Protocols.

[40]  J. Mascola,et al.  High throughput HIV-1 microneutralization assay , 2013 .

[41]  Young Do Kwon,et al.  Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. , 2013, Immunity.

[42]  B. Haynes,et al.  HIV‐1 neutralizing antibodies: understanding nature's pathways , 2013, Immunological reviews.

[43]  G. Learn,et al.  Heterogeneity in Neutralization Sensitivities of Viruses Comprising the Simian Immunodeficiency Virus SIVsmE660 Isolate and Vaccine Challenge Stock , 2013, Journal of Virology.

[44]  Sjors H.W. Scheres,et al.  RELION: Implementation of a Bayesian approach to cryo-EM structure determination , 2012, Journal of structural biology.

[45]  J. Mascola,et al.  Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. , 2012, Immunity.

[46]  Baoshan Zhang,et al.  Broad and potent neutralization of HIV-1 by a gp41-specific human antibody , 2012, Nature.

[47]  Guido Ferrari,et al.  Immune-correlates analysis of an HIV-1 vaccine efficacy trial. , 2012, The New England journal of medicine.

[48]  G. Silvestri,et al.  Natural SIV Hosts: Showing AIDS the Door , 2012, Science.

[49]  B. Korber,et al.  Distinct Evolutionary Pressures Underlie Diversity in Simian Immunodeficiency Virus and Human Immunodeficiency Virus Lineages , 2012, Journal of Virology.

[50]  Pham Phung,et al.  Broad neutralization coverage of HIV by multiple highly potent antibodies , 2011, Nature.

[51]  Mario Roederer,et al.  Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing , 2011, Science.

[52]  B. Korber,et al.  The TRIM5 Gene Modulates Penile Mucosal Acquisition of Simian Immunodeficiency Virus in Rhesus Monkeys , 2011, Journal of Virology.

[53]  D. Montefiori,et al.  Significant Protection against High-Dose Simian Immunodeficiency Virus Challenge Conferred by a New Prime-Boost Vaccine Regimen , 2011, Journal of Virology.

[54]  L. Morris,et al.  The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4+ T Cell Decline and High Viral Load during Acute Infection , 2011, Journal of Virology.

[55]  T. Miura,et al.  Isolation of potent neutralizing monoclonal antibodies from an SIV-Infected rhesus macaque by phage display. , 2010, AIDS research and human retroviruses.

[56]  Tongqing Zhou,et al.  Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01 , 2010, Science.

[57]  Mario Roederer,et al.  Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2010, Science.

[58]  Dennis R. Burton,et al.  A Limited Number of Antibody Specificities Mediate Broad and Potent Serum Neutralization in Selected HIV-1 Infected Individuals , 2010, PLoS pathogens.

[59]  H. Schuitemaker,et al.  Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression , 2009, AIDS.

[60]  Holly Janes,et al.  Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies , 2009, Journal of Virology.

[61]  Richard T. Wyatt,et al.  Breadth of Human Immunodeficiency Virus-Specific Neutralizing Activity in Sera: Clustering Analysis and Association with Clinical Variables , 2009, Journal of Virology.

[62]  Terri Wrin,et al.  Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm , 2009, Journal of Virology.

[63]  K. Abel,et al.  Enhanced in vivo immunogenicity of SIV vaccine candidates with cationic liposome-DNA complexes in a rhesus macaque pilot study , 2009, Human vaccines.

[64]  B. Korber,et al.  Partial Protection of Simian Immunodeficiency Virus (SIV)-Infected Rhesus Monkeys against Superinfection with a Heterologous SIV Isolate , 2009, Journal of Virology.

[65]  S. Staprans,et al.  Virus Subtype-Specific Features of Natural Simian Immunodeficiency Virus SIVsmm Infection in Sooty Mangabeys , 2007, Journal of Virology.

[66]  R. Desrosiers,et al.  Virion Envelope Content, Infectivity, and Neutralization Sensitivity of Simian Immunodeficiency Virus , 2005, Journal of Virology.

[67]  D. Montefiori,et al.  Evaluating Neutralizing Antibodies Against HIV, SIV, and SHIV in Luciferase Reporter Gene Assays , 2004, Current protocols in immunology.

[68]  R. Means,et al.  Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus , 1997, Journal of virology.

[69]  R. Desrosiers,et al.  Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys , 1993, Journal of virology.

[70]  P. Johnson,et al.  Genetic variation of simian immunodeficiency viruses in nonhuman primates. , 1992, AIDS research and human retroviruses.

[71]  R. Desrosiers,et al.  The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus. , 1990, AIDS research and human retroviruses.